FORT WORTH, Texas, Nov. 5, 2012 /PRNewswire/ -- Healthpoint Biotherapeutics today announced the introduction of a 5 cm x 7 cm size of OASIS® Ultra Tri-Layer Matrix, a naturally-derived extracellular matrix (ECM) material formed from three layers of porcine small intestinal submucosa (SIS). The three-layer construct of ECM was designed to provide increased structure for difficult-to-heal and chronic wounds.
"The triple-layer SIS technology in OASIS® Ultra has significantly changed the way I am able to take care of my patients. OASIS® Ultra provides physicians with an easy- to-work-with material that features improved handling to facilitate placement and fixation, as well as increased structure and greater durability to minimize disruption to forming tissue," noted Dr. Ally-Khan Somani, Assistant Professor and Director of Dermatologic Surgery and Cutaneous Oncology Division, Division of Dermatology, Indiana University School of Medicine. "The new 5x7 size is a welcome option for managing chronic wounds, particularly in outpatient sites of care."
SIS, the base technology for OASIS® Ultra, is among the most widely studied and published biomaterials, featured in more than 832 scientific publications.
"Since Healthpoint introduced the 7 cm x 10 cm and 7 cm x 20 cm sizes of OASIS® Ultra 18 months ago, physicians have reported high levels of satisfaction with the technology's improved handling on large wound types where products with increased strength and thickness are preferred," commented Travis Baugh, President and Chief Operating Officer of Healthpoint Biotherapeutics. "Building on this success, we are very pleased to introduce the 5x7 size of OASIS® Ultra to bring the same benefits to the many clinicians treating smaller chronic wounds, especially in outpatient sites of care."
Healthcare professionals seeking more information about the full range of the OASIS® Ultra product line may call 800-441-8227 to speak to a Healthpoint Biotherapeutics customer care specialist.
About OASIS® Wound Matrix and OASIS® Ultra
OASIS® Wound Matrix and OASIS® Ultra are indicated for the management of surgical wounds, including donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, and wound dehiscence, partial- and full-thickness wounds, trauma wounds (including second-degree burns), venous ulcers, chronic vascular ulcers, diabetic ulcers, pressure ulcers, and draining wounds. These devices are derived from a porcine source and should not be used in patients with known sensitivity to porcine material. These devices are not indicated for use in third-degree burns.
About Healthpoint Biotherapeutics
Healthpoint Biotherapeutics is a biopharmaceutical company focused on the development and commercialization of novel, cost-effective solutions for dermal repair and regeneration. The company's research and development strategy is centered around next-generation bioactive therapies for the treatment of chronic wounds. Currently marketed products include Collagenase SANTYL® Ointment, OASIS® Wound Matrix, OASIS® Ultra Tri-Layer Matrix and REGRANEX® (becaplermin) Gel 0.01%. Healthpoint Biotherapeutics is also committed to advancing the care and treatment of wounds through support of industry leading continuing education from The Wound Institute®. To learn more about this comprehensive and award winning educational resource, please visit TheWoundInstitute.com®. Healthpoint Biotherapeutics is a DFB Pharmaceuticals, Inc., affiliate company, and is based in Fort Worth, Texas. For more information, visit the company website at www.Healthpointbio.com.
HEALTHPOINT and related logo, SANTYL, THE WOUND INSTITUTE, THEWOUNDINSTITUTE.COM and REGRANEX are registered trademarks of Healthpoint, Ltd.
OASIS is a registered trademark of Cook Biotech, Inc.
SOURCE Healthpoint Biotherapeutics